Social Media Listening for Routine Post-Marketing Safety Surveillance

被引：0
|
作者：
Gregory E. Powell
Harry A. Seifert
Tjark Reblin
Phil J. Burstein
James Blowers
J. Alan Menius
Jeffery L. Painter
Michele Thomas
Carrie E. Pierce
Harold W. Rodriguez
John S. Brownstein
Clark C. Freifeld
Heidi G. Bell
Nabarun Dasgupta
机构：
[1] GlaxoSmithKline,
[2] GlaxoSmithKline Vaccines,undefined
[3] GlaxoSmithKline,undefined
[4] GlaxoSmithKline,undefined
[5] Blue Zone Industries,undefined
[6] Epidemico Inc.,undefined
[7] Zero Chaos,undefined
来源：
Drug Safety | 2016年 / 39卷
关键词：
Social Medium; Anatomical Therapeutic Chemical; Indicator Score; Proportional Reporting Ratio; Twitter Data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：443 / 454
页数：11
相关论文
共 50 条
  • [31] Post-marketing surveillance of novel foods
    Warner, JO
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2002, 13 (06) : 385 - 385
  • [32] POST-MARKETING SURVEILLANCE - DRUG EPIDEMIOLOGY
    BORDEN, EK
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1981, 9 (06) : 401 - 407
  • [33] Optimization of the post-marketing surveillance procedure
    Kalle, Parminder
    [J]. ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (02) : 125 - 127
  • [34] POST-MARKETING SURVEILLANCE OF OFLOXACIN IN JAPAN
    YAMADA, A
    NAKAMURA, S
    TAKAHASHI, K
    SAWADA, M
    OKADA, S
    [J]. REVIEWS OF INFECTIOUS DISEASES, 1989, 11 : S1409 - S1409
  • [35] Post-marketing stability surveillance: Amoxicillin
    Naidoo, K. K.
    Nompuku, P.
    Mkalali, S. N.
    Shabangu, K.
    Nkabinde, L.
    Singh, V
    [J]. SOUTH AFRICAN FAMILY PRACTICE, 2006, 48 (06) : 14 - +
  • [36] POST-MARKETING SURVEILLANCE OF MEDICINES IN THE UK
    GRIFFIN, JP
    BAKER, R
    [J]. PHARMACY INTERNATIONAL, 1981, 2 (09): : 203 - 209
  • [37] Sodium Oxybate Post-Marketing Surveillance
    Feldman, Neil T.
    [J]. JOURNAL OF CLINICAL SLEEP MEDICINE, 2011, 7 (04): : 417 - 417
  • [38] Characteristics of post-marketing studies and their contribution to post-marketing safety measures in Japan
    Kanmuri K.
    Narukawa M.
    [J]. Pharmaceutical Medicine, 2014, 28 (2) : 67 - 73
  • [39] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    Ohashi, Satoshi
    Koga, Tadashi
    Toyoda, Tetsumi
    Ishii, Mika
    [J]. DRUGS-REAL WORLD OUTCOMES, 2019, 6 (01) : 27 - 35
  • [40] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Yukinori Sakata
    Toshiyuki Matsuoka
    Satoshi Ohashi
    Tadashi Koga
    Tetsumi Toyoda
    Mika Ishii
    [J]. Drugs - Real World Outcomes, 2019, 6 : 27 - 35
12345